Core Insights - SOPHiA GENETICS reported financial results for Q4 and FY 2024, highlighting a record number of analyses and new customer acquisitions despite challenges in the BioPharma sector [2][6][20] Financial Highlights - Q4 2024 revenue was $17.7 million, a 4% increase year-over-year, and FY 2024 revenue reached $65.2 million, also up 4% year-over-year [6][22] - Gross margin for Q4 2024 was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year [6][32] - Operating loss for Q4 2024 was $17.4 million, improving by 8% year-over-year, while FY 2024 operating loss was $66.6 million, improving by 11% year-over-year [6][22] Business Highlights - The company performed a record 352,000 analyses in FY 2024, representing an 11% year-over-year volume growth [7] - SOPHiA GENETICS expanded its customer base to 472 core genomics customers by the end of FY 2024, up from 450 at the end of Q4 2023 [7] - The company signed a record 92 new customers in FY 2024, including 31 in Q4 2024, who will implement SOPHiA DDM™ and begin generating revenue [7] Product Development and Market Expansion - The launch of the Liquid Biopsy application MSK-ACCESS® in Q2 2024 attracted 34 customers, with 15 implementations completed by the end of FY 2024 [7][10] - The company entered into a collaboration with Genesis Healthcare Co. in Japan to enhance access to genomic testing and support BioPharma companies [7] - SOPHiA GENETICS is focused on operational excellence, with an adjusted operating loss improvement of 23% year-over-year in Q4 2024 [10] 2025 Financial Outlook - The company expects full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to FY 2024 [10] - Adjusted EBITDA loss is projected to be between $35 million and $39 million, compared to $40.2 million in FY 2024 [10]

Core Insights - SOPHiA GENETICS has achieved a significant milestone in the global adoption of its cancer testing applications, with 37 institutions adopting the MSK-ACCESS® and MSK-IMPACT® applications powered by SOPHiA DDM™ [1][5][8] Group 1: Adoption and Impact - 34 out of the 37 institutions have adopted the MSK-ACCESS® application within 10 months of its launch, enabling decentralized Liquid Biopsy testing [5] - The decentralized deployment allows institutions to provide less-invasive genomic testing options, resulting in lower costs and faster turnaround times while retaining control over patient data [5] - Notable institutions adopting these applications include Heidelberg University Hospital, Biopticka Laboratory, and Jewish General Hospital [6][7] Group 2: Collaborations and Future Prospects - SOPHiA GENETICS partnered with Memorial Sloan Kettering Cancer Center in 2023 to enhance cancer testing capabilities globally [8] - A definitive partnership with AstraZeneca was announced in October 2024 to accelerate the deployment of MSK-ACCESS® [8] - These collaborations aim to transform cancer research by leveraging real-world data and advanced technology [8] Group 3: Expert Endorsements - Professor Umberto Malapelle from the University Federico II of Naples supports the new applications for cancer research, highlighting the collaborative potential of SOPHiA GENETICS [2][3] - Ross Muken, President of SOPHiA GENETICS, emphasized the importance of bringing advanced technology to global organizations for improved healthcare [4]

BOSTON and ROLLE, Switzerland, Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.The call will be webcast ...

The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to a ...

Financial Data and Key Metrics - Q3 2024 revenue was $15.9 million, a 2.5% YoY decline, primarily due to a $2 million drop in biopharma revenue [21] - Adjusted gross margin improved to 73.1% in Q3 2024, up 60 basis points YoY, despite revenue softness [24] - Operating loss improved by 7% YoY to $15.4 million, with adjusted operating loss improving by 10% to $10.6 million [26] - Cash burn decreased by 39% YoY to $9.6 million, with cash and cash equivalents at $95.8 million as of September 30, 2024 [27] - Full-year 2024 revenue guidance reaffirmed at $65-67 million, representing 4-7% YoY growth [28] Business Line Performance - Clinical analysis volume grew 16% YoY (17% excluding COVID-related volumes) to 91,000 analyses in Q3 2024 [8] - Biopharma revenue declined materially in Q3, but the pipeline remains healthy, suggesting a recovery in 2025 [9] - Hemon testing and rare/inherited disease portfolio grew 26% and 29% YoY, respectively [20] - MSK-ACCESS adoption reached 18 customers across 5 continents, with 5 already in routine usage [13][14] Market Performance - North America and Asia Pacific grew approximately 30% YoY, while EMEA returned to company average growth [20] - Latin America faced challenges due to the churn of a large account, partially offsetting growth in other regions [21] - Spain remained weak due to reimbursement dynamics in the solid tumor market, with softness expected to persist into 2025 [20] Strategy and Industry Competition - The company is focused on decentralized testing through MSK-ACCESS and MSK-IMPACT, enabling hospitals to conduct liquid biopsy and solid tumor testing in-house [12][14] - Biopharma partnerships, such as with AstraZeneca, are leveraging SOPHiA's network for drug deployment and market access [15] - The company is positioning itself as a leader in data-driven medicine, with a strong focus on oncology and rare diseases [30] Management Commentary on Operating Environment and Future Outlook - Management remains confident in the path to profitability, with strong cost management and operational leverage [26] - The company expects a reacceleration of growth in 2025, driven by clinical volume recovery and biopharma momentum [9][42] - Cancer rates are increasing globally, and the company is well-positioned to capitalize on the growing demand for data-driven diagnostics and therapies [30] Other Important Information - Ross Muken was promoted to Company President, overseeing global business operations [17] - George Cardoza joined as CFO, bringing extensive financial and scaling expertise [18] - The company is presenting at the Guggenheim Healthcare Conference in Boston [31] Q&A Session Summary Question: MSK-ACCESS and MSK-IMPACT Growth Potential - MSK-ACCESS has been adopted by 18 customers globally, with 5 already in routine usage, and is expected to contribute materially to growth in 2025 [34][37] - MSK-IMPACT, launched in October, is expected to complement MSK-ACCESS, with strong demand anticipated [35] - Biopharma interest in decentralized testing is growing, providing additional growth opportunities [39] Question: 2025 Growth Acceleration - The company is confident in reaccelerating growth in 2025, driven by clinical volume recovery and biopharma momentum [41][42] - MSK-based products and new customer onboarding are expected to be key growth drivers [42] Question: Pricing Trends - Pricing pressure in Europe, particularly in Spain, has stabilized in France and Italy, with overall pricing expected to improve in 2025 [45][46] - Newer products with higher ASPs are expected to drive overall pricing improvements [46] Question: Biopharma Recovery - Biopharma revenue is expected to stabilize and improve in 2025, with a focus on post-approval activities and market access [50][53] - The company has a strong pipeline and is well-positioned to capitalize on biopharma demand for decentralized testing [53] Question: Clinical Volume Growth - Clinical volume growth remains strong, with North America and Asia Pacific leading the way [65] - The company is not seeing a market slowdown in clinical sequencing volumes, with robust demand for complex tests like liquid biopsy and MRD [67] Question: Biopharma Spending Dynamics - Biopharma budget constraints have impacted pre-approval activities, but the company is refocusing on post-approval activities to drive growth [70]

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim C ...

Company Leadership Changes - Ross Muken has been promoted to President of SOPHiA GENETICS, effective November 5, 2024, overseeing global business operations and strategic planning alongside CEO Jurgi Camblong [1][2] - George Cardoza has been appointed as the new CFO, responsible for all corporate finance functions including accounting, financial planning and analysis, investor relations, internal audit, tax, and treasury [2][3] Executive Backgrounds - Ross Muken joined SOPHiA GENETICS in February 2021 as CFO and became CFO and COO in March 2023, playing a key role in the company's success [1][2] - George Cardoza brings over 30 years of experience in the precision medicine and clinical diagnostics industry, having held executive roles at Biocartis and NeoGenomics Laboratories [3][4] Company Mission and Technology - SOPHiA GENETICS is a cloud-native healthcare technology company focused on expanding access to data-driven medicine using AI to provide care for patients with cancer and rare disorders [5] - The company developed SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data to generate actionable insights for hospitals, laboratories, and biopharma institutions [5]

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39%BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72. ...

BOSTON and ROLLE, Switzerland, Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.The call will be webc ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI ...